World Asthma Day: Alkem Labs collaborates with 100 hospitals in Tier-1 & Tier-2 cities

New Delhi: In recognition of World Asthma Day 2024, Alkem Laboratories (Alkem) today announced 600 to 700 camps across India, collaborating with nearly 100 hospitals in tier-1 and tier-2 cities under its “Reliever Free India” initiative.

This nationwide initiative was launched in 2023 with an aim to revolutionize asthma management by advocating for a shift in focus from reliance on reliever medications to the importance of controller medications.

Reliever medications provide quick relief during asthma symptoms by opening up the airways. Controller medications are taken regularly to prevent asthma symptoms and reduce inflammation in the airways. After a successful first year, Alkem is intensifying the campaign in its second year.

Asthma affects a staggering 262 million people globally, causing recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Despite advancements in medical treatment, asthma remains a significant challenge for patients and healthcare providers alike. Alkem recognizes the critical role that education plays in empowering individuals to effectively manage their asthma and lead fulfilling lives.

Alkem Laboratories Spokesperson said, “We’ve engaged with over 500 camps since the start of our campaign. This year, we’re expanding our commitment by organizing at least 600 camps and clinics to raise awareness about asthma and its management. Our goal is to empower patients with the knowledge they need to take control of their health. Through the ‘Reliever Free India’ campaign, we’re promoting a proactive approach to asthma management, aiming to improve outcomes and enhance quality of life for individuals with this condition.”

The “Reliever Free India” campaign emphasizes the importance of using controller medications for optimal asthma management. While reliever medications offer immediate relief during asthma attacks, they do not address the underlying inflammation that contributes to the condition’s chronic nature. Over-reliance on relievers can lead to poor long-term outcomes and increased risk of exacerbations. Through this campaign, Alkem Laboratories seeks to educate patients, healthcare professionals, and the general public about the benefits of controller medications in preventing asthma symptoms and reducing the need for rescue medication.

This World Asthma Day, Alkem Laboratories invites everyone to join hands in raising awareness, fostering understanding, and empowering individuals with asthma to live their lives to the fullest. Together, we can create a world where asthma is not a barrier to a healthy and fulfilling life.